Connor Clark & Lunn Investment Management Ltd. Buys Shares of 14,946 Henry Schein, Inc. $HSIC

Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 14,946 shares of the company's stock, valued at approximately $1,024,000.

Other hedge funds have also modified their holdings of the company. Guggenheim Capital LLC increased its stake in Henry Schein by 2.5% in the 4th quarter. Guggenheim Capital LLC now owns 6,428 shares of the company's stock valued at $445,000 after purchasing an additional 159 shares in the last quarter. UMB Bank n.a. lifted its stake in shares of Henry Schein by 23.2% in the first quarter. UMB Bank n.a. now owns 1,066 shares of the company's stock worth $73,000 after acquiring an additional 201 shares in the last quarter. Humankind Investments LLC lifted its stake in shares of Henry Schein by 7.4% in the fourth quarter. Humankind Investments LLC now owns 3,057 shares of the company's stock worth $212,000 after acquiring an additional 211 shares in the last quarter. HB Wealth Management LLC increased its holdings in Henry Schein by 1.5% in the first quarter. HB Wealth Management LLC now owns 15,419 shares of the company's stock valued at $1,056,000 after buying an additional 226 shares during the last quarter. Finally, J. Safra Sarasin Holding AG grew its holdings in shares of Henry Schein by 1.1% during the fourth quarter. J. Safra Sarasin Holding AG now owns 22,098 shares of the company's stock valued at $1,529,000 after purchasing an additional 231 shares during the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

Henry Schein Stock Performance

Shares of NASDAQ:HSIC traded up $0.33 on Wednesday, reaching $68.64. 2,059,320 shares of the company's stock were exchanged, compared to its average volume of 1,773,886. The company has a current ratio of 1.41, a quick ratio of 0.78 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $8.32 billion, a price-to-earnings ratio of 22.14, a PEG ratio of 2.22 and a beta of 0.81. The company has a fifty day moving average of $70.67 and a 200-day moving average of $70.61. Henry Schein, Inc. has a twelve month low of $60.56 and a twelve month high of $82.49.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.19 by ($0.09). The firm had revenue of $3.24 billion for the quarter, compared to analyst estimates of $3.22 billion. Henry Schein had a return on equity of 14.36% and a net margin of 3.05%.The business's revenue was up 3.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.23 EPS. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. On average, research analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on HSIC. Stifel Nicolaus reaffirmed a "hold" rating and set a $75.00 price target (down from $80.00) on shares of Henry Schein in a research note on Friday, July 25th. Barrington Research decreased their price objective on Henry Schein from $86.00 to $78.00 and set an "outperform" rating on the stock in a report on Wednesday, August 6th. JPMorgan Chase & Co. cut their target price on shares of Henry Schein from $80.00 to $76.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. Leerink Partners set a $75.00 price objective on shares of Henry Schein in a research report on Monday, July 14th. Finally, UBS Group dropped their target price on shares of Henry Schein from $75.00 to $70.00 and set a "neutral" rating for the company in a research report on Wednesday, August 6th. Four investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $75.58.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.